China Universal Asset Management Co. Ltd. raised its holdings in Wave Life Sciences Ltd. (NASDAQ:WVE - Free Report) by 126.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 54,267 shares of the company's stock after acquiring an additional 30,276 shares during the quarter. China Universal Asset Management Co. Ltd.'s holdings in Wave Life Sciences were worth $671,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Wave Life Sciences by 23.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,512 shares of the company's stock worth $37,000 after buying an additional 856 shares during the last quarter. Mackenzie Financial Corp boosted its position in shares of Wave Life Sciences by 13.6% during the second quarter. Mackenzie Financial Corp now owns 15,887 shares of the company's stock worth $79,000 after purchasing an additional 1,905 shares in the last quarter. Kraematon Investment Advisors Inc. increased its position in shares of Wave Life Sciences by 24.3% in the 4th quarter. Kraematon Investment Advisors Inc. now owns 19,885 shares of the company's stock valued at $246,000 after buying an additional 3,885 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Wave Life Sciences by 3.6% during the second quarter. The Manufacturers Life Insurance Company now owns 139,790 shares of the company's stock worth $698,000 after purchasing an additional 4,914 shares during the period. Finally, KBC Group NV acquired a new position in shares of Wave Life Sciences in the 4th quarter valued at approximately $67,000. Institutional investors own 89.73% of the company's stock.
Insider Buying and Selling at Wave Life Sciences
In other Wave Life Sciences news, CEO Paul Bolno sold 50,000 shares of Wave Life Sciences stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $15.00, for a total transaction of $750,000.00. Following the completion of the sale, the chief executive officer now directly owns 217,351 shares in the company, valued at $3,260,265. The trade was a 18.70 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Chris Francis sold 36,000 shares of the stock in a transaction on Friday, November 8th. The stock was sold at an average price of $16.00, for a total transaction of $576,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 137,234 shares of company stock worth $2,059,671 over the last three months. 29.10% of the stock is currently owned by insiders.
Wave Life Sciences Stock Up 5.4 %
NASDAQ WVE traded up $0.63 on Wednesday, hitting $12.37. The company's stock had a trading volume of 305,158 shares, compared to its average volume of 877,479. The firm has a market cap of $1.89 billion, a PE ratio of -11.13 and a beta of -1.09. Wave Life Sciences Ltd. has a 1-year low of $3.50 and a 1-year high of $16.74. The company's 50-day moving average is $12.99 and its 200 day moving average is $10.50.
Analysts Set New Price Targets
Several equities research analysts have recently issued reports on the stock. Leerink Partners increased their price objective on shares of Wave Life Sciences from $20.00 to $22.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 16th. Mizuho boosted their price objective on shares of Wave Life Sciences from $19.00 to $22.00 and gave the stock an "outperform" rating in a research report on Thursday, November 21st. B. Riley raised their target price on shares of Wave Life Sciences from $19.00 to $22.00 and gave the company a "buy" rating in a research report on Monday, November 4th. HC Wainwright reissued a "buy" rating and set a $22.00 price target on shares of Wave Life Sciences in a research report on Wednesday, November 13th. Finally, Wells Fargo & Company lifted their target price on Wave Life Sciences from $11.00 to $22.00 and gave the company an "overweight" rating in a research report on Wednesday, October 16th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $22.22.
Check Out Our Latest Report on Wave Life Sciences
Wave Life Sciences Profile
(
Free Report)
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.
See Also
Before you consider Wave Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Wave Life Sciences wasn't on the list.
While Wave Life Sciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
